A RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT-NAIVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER

Trial Profile

A RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT-NAIVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2018

At a glance

  • Drugs Alectinib (Primary) ; Crizotinib
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ALEX
  • Sponsors Roche
  • Most Recent Events

    • 13 Jun 2018 According to a Roche media release, Health Canada has approved ALECENSARO as a monotherapy for the first-line treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC), based on the results of this trial.
    • 05 Jun 2018 Results of updated efficacy and safety data (data cut off: Dec 1, 2017) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Results of pooled data from (J-ALEX; JapicCTI-132316) and global (ALEX; NCT02075840) (n=95), were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top